LGALS3 and familial dilated cardiomyopathy: Reducing ventricular dilation, congestion, and fibrosis through the suppression of Gal-3 mRNA expression in Mst1-TG mice, which model DCM with high levels of cardiac Gal-3, is a promising therapeutic approach [109].